Lilly and Novo Post 340B Refund Notices, Amgen Posts 340B Replenishment Notice

Eli Lily and Novo Nordisk
Lilly and Novo Nordisk are refunding 340B covered entities on some products due to 340B ceiling price adjustments.
Drugmakers Lilly and Novo Nordisk are giving covered entities refunds on some products due to 340B ceiling price adjustments, according [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Transparency, Patient Assistance Requirements Needed in 340B, Say Drugmaker-Backed Groups

Justin Leventhal
Justin Leventhal, a senior policy analyst for the American Consumer Institute, has advocated for more 340B transparency alongside other drugmaker-backed groups.
Amid ongoing congressional legislative proposals to boost transparency and other requirements for 340B hospitals, two advocacy groups that receive drugmaker [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Providers Try a Range of Responses to Manufacturer 340B Contract Pharmacy Restrictions

Colleen Meiman
Community health centers are attempting to mitigate the adverse financial effects of manufacturer 340B contract pharmacy restrictions on their organizations, said Colleen Meiman, national policy advisor for State & Regional Associations of Community Health Centers.
Amid an increasing number of drugmaker restrictions and requirements on the use of contract pharmacies, 340B providers are trying a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Federal Appeals Court Judges Press Both Sides in Key Hearing on Arkansas 340B Contract Pharmacy Law

Chief Judge Lavenski Smith of the 8th Circuit Court of Appeals and two other federal judges heard highly anticipated oral arguments for PhRMA v. McClain in a case that challenges Arkansas' 340B contract pharmacy law.
Attorneys representing Arkansas and 340B providers sparred with a drug industry lawyer over the constitutionality of Arkansas’ first-in-the-nation 340B contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Teva Ends 340B Contract Pharmacy Restrictions in Arkansas in Response to State Law

Teva
The final HRSA manufacturer 340B program audit conducted in fiscal year 2023 had no adverse findings for Teva Pharmaceuticals.
Teva Pharmaceuticals this week ended its 340B contract pharmacy restrictions in Arkansas in response to a state law that prevents [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Incyte Becomes 26th Drugmaker to Place Contract Pharmacy Restrictions

Incyte will no longer allow 340B hospitals to have direct delivery of Opzelura products purchased at the 340B discount price to contract pharmacies.
Drug manufacturer Incyte Corp. this week announced it will become the 26th drug manufacturer to restrict access to 340B pricing when [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Novo Nordisk Providing 340B Refunds on Blockbuster Drug Ozempic

Ozempic package
Drugmaker Novo Nordisk is issuing 340B refunds for certain purchases of its blockbuster diabetes medication Ozempic.
Novo Nordisk will issue refunds to 340B covered entities for some purchases this year of its blockbuster injectable diabetes medication [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Louisiana AG Defends State 340B Contract Pharmacy Law Against Drug Industry Lawsuit

Jeff Landry headshot
Four hospital associations filed an amicus brief in support of Louisiana Attorney General Jeff Landry's defense of his state's contract pharmacy law.
The Louisiana attorney general recently asked a federal district judge to dismiss a drug industry lawsuit that challenges Louisiana’s 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Two More Drugmakers Owe 340B Provider Repayments, HRSA Audits Find

HRSA headquarters
A HRSA manufacturer audit found that drugmakers Cencora and Medefil Inc. owe repayments to 340B providers.
Two drugmakers owe repayment to 340B covered entities, according to final audits posted this week by federal officials. American Health [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Jazz Pharmaceuticals Is 25th Drugmaker to Implement Contract Pharmacy Restrictions

Jazz Pharmaceuticals owes refunds to 340B providers, according to a notice posted on HRSA's website.
Drug manufacturer Jazz Pharmaceuticals this week became the 25th drug manufacturer to impose conditions on 340B pricing involving delivery to contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report